|By JCN Newswire||
|August 18, 2014 02:50 AM EDT||
Based on this agreement, Eisai will grant Zeria the exclusive rights to develop and co-promote, and the non-exclusive right to manufacture, E3710 in Japan. In addition, Eisai will receive down payment and additional royalties from Zeria, and after marketing authorization has been successfully obtained, Eisai will pay Zeria a certain consideration. While Zeria will develop E3710 and work to obtain marketing authorization, the two companies will collaborate on marketing E3710 after launch.
E3710 is a novel PPI discovered by Eisai as a successor to Pariet, and compared to existing PPIs, potentially provides a stronger and a longer-lasting inhibitory effect on gastric acid secretion. E3710 shows promise as a best-in-class treatment which could shorten the treatment period and meet the needs of patients for whom existing PPIs are inadequate.
This license agreement will enhance the product pipeline of Zeria, who focuses on gastrointestinal diseases as a key franchise area, and maximize the value of Eisai's compound. Both Eisai and Zeria have a strong track record in the field of gastrointernal diseases (Eisai with the PPI Pariet and the gastritis / gastric ulcer treatment Selbex, Zeria with the ulcerative colitis treatment Asacol and the world's first functional dyspepsia treatment Acofide) and will conduct co-promotional activities with the aim of bringing a product to the market for acid related diseases as soon as possible.
Through this collaboration on E3710, Eisai and Zeria aim to satisfy the medical needs of acid related diseases and further contribute to the treatment of patients.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net
Apr. 27, 2017 05:00 AM EDT Reads: 2,245
Apr. 27, 2017 04:45 AM EDT Reads: 5,399
Apr. 27, 2017 03:45 AM EDT Reads: 1,546
Apr. 27, 2017 03:45 AM EDT Reads: 3,699
Apr. 27, 2017 03:30 AM EDT Reads: 767
Apr. 27, 2017 03:15 AM EDT Reads: 2,123
Apr. 27, 2017 03:15 AM EDT Reads: 5,962
Apr. 27, 2017 03:15 AM EDT Reads: 1,163
Apr. 27, 2017 02:30 AM EDT Reads: 1,463
Apr. 27, 2017 02:15 AM EDT Reads: 830
Apr. 27, 2017 01:15 AM EDT Reads: 1,500
Apr. 27, 2017 12:45 AM EDT Reads: 617
Apr. 27, 2017 12:00 AM EDT Reads: 9,137
Apr. 27, 2017 12:00 AM EDT Reads: 726
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...
Apr. 26, 2017 11:15 PM EDT Reads: 2,260